https://scholars.lib.ntu.edu.tw/handle/123456789/487330
標題: | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | 作者: | CHIH-HUNG HSU Yang T.-S. CHIUN HSU Toh H.C. Epstein R.J. Hsiao L.-T. PEI-JER CHEN ZHONG-ZHE LIN Chao T.-Y. ANN-LII CHENG |
公開日期: | 2010 | 出版社: | Nature Publishing Group | 卷: | 102 | 期: | 6 | 起(迄)頁: | 981-986 | 來源出版物: | British Journal of Cancer | 摘要: | Background: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population. Methods: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5 mg kg-1 on day 1 and capecitabine 800 mg m-2 twice daily on days 1-14 every 3 weeks as first-line therapy.Results: A total of 45 patients were enrolled; 44 (96%) had extrahepatic metastasis and/or major vessel invasion and 30 (67%) had hepatitis B. No grade 3/4 haematological toxicity occurred. Treatment-related grade 3/4 non-haematological toxicities included diarrhoea (n=2, 4%), nausea/vomiting (n=1, 2%), gastrointestinal bleeding (n=4, 9%) and hand-foot syndrome (n=4, 9%). The overall response rate (RECIST) was 9% and the disease control rate was 52%. Overall, median progression-free survival (PFS) and overall survival (OS) were 2.7 and 5.9 months, respectively. Median PFS and OS were 3.6 and 8.2 months, respectively, for Cancer of the Liver Italian Programme (CLIP) score?3 patients, and 1.4 and 3.3 months, respectively, for CLIP score 4 patients.Conclusion: The bevacizumab-capecitabine combination shows good tolerability and modest anti-tumour activity in patients with advanced HCC. ? 2010 Cancer Research UK All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984578313&doi=10.1038%2fsj.bjc.6605580&partnerID=40&md5=de734beec9d964886128452d574614d3 https://scholars.lib.ntu.edu.tw/handle/123456789/487330 |
ISSN: | 0007-0920 | DOI: | 10.1038/sj.bjc.6605580 | SDG/關鍵字: | bevacizumab; capecitabine; advanced cancer; anemia; article; blood toxicity; cancer invasion; clinical article; clinical trial; controlled study; diarrhea; disease control; drug dose reduction; drug efficacy; drug tolerability; drug withdrawal; esophagus varices; female; gastrointestinal hemorrhage; hand foot syndrome; hepatitis; human; hyperbilirubinemia; hypoalbuminemia; hyponatremia; liver cell carcinoma; liver metastasis; lower respiratory tract infection; male; mucosa inflammation; multicenter study; multiple cycle treatment; nausea; neutropenia; overall survival; phase 2 clinical trial; priority journal; progression free survival; proteinuria; side effect; skin pigmentation; thrombocytopenia; treatment response; vomiting; weight reduction |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。